Pharsight

1. Prialt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5795864	TERSERA	Stable omega conopetide formulations	Jun, 2015 (8 years ago)
US5364842	TERSERA	Method of producing analgesia	Dec, 2016 (7 years ago)
US8653033	TERSERA	Method for administering omega-conopeptide	Oct, 2024 (5 months from now)
US8765680	TERSERA	Method for administering omega-conopeptide	Oct, 2024 (5 months from now)
US9707270	TERSERA	Method for administering ω-conopeptide	Oct, 2024 (5 months from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

Strength	Dosage	Availability
500MCG/20ML (25MCG/ML)	INJECTABLE;INTRATHECAL	Prescription
100MCG/1ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Prescription
200MCG/2ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Discontinued
500MCG/5ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Prescription

PRIALT family patents

2. Qmiiz Odt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879	TERSERA	Fast disintegrating compositions of meloxicam	Aug, 2030 (6 years from now)

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
7.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

QMIIZ ODT family patents

3. Varubi patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP07774640A	2017-03-08	Teva Pharmaceutical Industries Ltd	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7049230	TERSERA	Method of forming a contact plug in a semiconductor device	Dec, 2023 (4 months ago)
US8178550	TERSERA	Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Apr, 2027 (2 years from now)
US7049320	TERSERA	NK1 antagonists	Aug, 2028 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299	TERSERA	NK1 antagonists	Dec, 2022 (1 year, 4 months ago)
US7981905	TERSERA	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (2 years from now)
US8404702	TERSERA	Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (2 years from now)
US7563801	TERSERA	Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same	Apr, 2027 (2 years from now)
US8470842	TERSERA	Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Jan, 2029 (4 years from now)
US8361500	TERSERA	Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom	Oct, 2029 (5 years from now)
US9101615	TERSERA	Intravenous formulations of neurokinin-1 antagonists	Jul, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 01, 2020

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS; TABLET;ORAL

Strength	Dosage	Availability
EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	EMULSION;INTRAVENOUS	Discontinued
EQ 90MG BASE	TABLET;ORAL	Prescription

VARUBI family patents

4. Xermelo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7553840	TERSERA	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use	Dec, 2027 (3 years from now)
US8193204	TERSERA	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use	Feb, 2031 (6 years from now)
US7709493	TERSERA	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use	Feb, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559	TERSERA	Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds	Dec, 2027 (3 years from now)
US8653094	TERSERA	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use	Dec, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-132)	Feb 28, 2024
Orphan Drug Exclusivity(ODE)	Feb 28, 2024
New Chemical Entity Exclusivity(NCE)	Feb 28, 2022

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: 28 February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 250MG BASE	TABLET;ORAL	Prescription

XERMELO family patents

5. Zoladex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500964	TERSERA	Automatically operable safety shield system for syringes	Feb, 2021 (3 years ago)
US7220247	TERSERA	Automatically operable safety shield system for syringes	Apr, 2022 (2 years ago)
US7118552	TERSERA	Automatically operable safety shield system for syringes	Apr, 2022 (2 years ago)

Drugs and Companies using GOSERELIN ACETATE ingredient

Market Authorisation Date: 11 January, 1996